Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for constant intravenous infusions or injections, which are painful as well as inconvenient.
Pfizer’s Hympavzi Approved for Treatment of Certain Types of Hemophilia
The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a week.
US FDA approves Pfizer's drug for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday.
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA approved a Pfizer treatment for hemophilia. On Friday the U.S. regulator signed off on Hympavzi,
Pfizer gets FDA approval for Hympavzi for hemophilia
Pfizer (NYSE:PFE) said the FDA has approved its drug Hympavzi for the treatment of certain types of hemophilia. The agency approved Hympavzi as a routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients aged 12 years and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX
2d
An Activist Investor Just Bought $1 Billion Worth of Pfizer. Here's What It Means for the Stock
On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer ( PFE -0.61%) ...
3d
Pfizer fight with Starboard heats up, hedge fund alleges executive pressure
The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...
STAT
2d
Pharmalittle: We’re reading about alleged Pfizer threats, industry payments to peer reviewers, and more
Starboard Value alleged that Pfizer officials threatened legal action against two former top executives who had been working ...
2d
on MSN
Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis
Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...
Wall Street Journal on MSN
3d
Activist Accuses Pfizer of Pressuring Former Executives
The fight between Starboard Value and drug giant
Pfizer
PFE-2.82%decrease; red down pointing triangle took an unusual, ...
FiercePharma
3d
Activist investor Starboard accuses Pfizer of strong-arming former execs into backing CEO Bourla ahead of strategy meeting
Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...
STAT
3d
A crack of light for Pfizer
Pfizer shared that the combination of its drugs Talzenna and Xtandi extended survival in men with metastatic ...
3d
Pfizer's CEO gains support of ex-execs amid activist investor talks
"We have decided not to be involved in the efforts of Starboard Value regarding Pfizer. We are fully supportive of Pfizer ...
3d
Pfizer's cancer drug combo improves overall survival in late-stage study
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Starboard
RSV vaccine
Stocks
Ian Read
Hympavzi
Feedback